Perakizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Perakizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target IL17A
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
Formula C6454H9964N1718O2030S44
Molar mass 145.4 kg/mol

Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis.[1] It binds to IL17A and acts as an immunomodulator.[2]

This drug was developed by Genentech/Roche.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Perakizumab, American Medical Association.
  2. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).